Table 1.
Efficacy and effectiveness of the live herpes zoster vaccine (ZVL) in adults.
| Efficacy | Effectiveness 1 | |||
|---|---|---|---|---|
| Author, Year | Oxman (2005) |
Schumader (2012) |
Tricco (2018) |
Mbinta (2022) |
| Age, years | ≥60 | ≥50 | ≥50 | ≥50 |
| Efficacy against HZ, % (95% CI) | ||||
| All patients | 51.3 (44.2–57.6) | 69.8 (54.1–80.6) | 57.0 (−61.0–84.0) | 45.9 (42.2–49.4) |
| 50–59 yrs | ----- | 69.8 (54.1–80.6) | ----- | 60.0 (53.0–65.0) |
| 60–69 yrs | 63.9 (N/A) | ----- | ----- | 50.9 (45.0–56.1) |
| 70–79 yrs | 37.6 (N/A) | ----- | ----- | 46.6 (40.7–51.9) |
| ≥80 | 18.0 (N/A) | ----- | ----- | 43.9 (37.7–49.5) |
| Efficacy against PHN, % (95% CI) | ||||
| All patients | 66.5 (47.5–79.2) | ----- | ----- | 59.7% (48.3–68.7) |
| 50–59 yrs | ----- | ----- | ----- | ----- |
| 60–69 yrs | 65.7 (20.4–86.7) | ----- | ----- | ----- |
| 70–79 yrs | 66.8 (43.3–81.3) | ----- | ----- | ----- |
| ≥80 | ----- | ----- | ----- | ----- |
1 Pooled vaccine effectiveness. Abbreviations: HZ—herpes zoster; PHN—post-herpetic neuralgia; CI—confidence interval.